首页> 外文期刊>Neonatology >Innovation in surfactant therapy I: Surfactant lavage and surfactant administration by fluid bolus using minimally invasive techniques
【24h】

Innovation in surfactant therapy I: Surfactant lavage and surfactant administration by fluid bolus using minimally invasive techniques

机译:表面活性剂疗法的创新I:使用微创技术通过液体推注的表面活性剂灌洗和表面活性剂给药

获取原文
获取原文并翻译 | 示例
       

摘要

Innovation in the field of exogenous surfactant therapy continues more than two decades after the drug became commercially available. One such innovation, lung lavage using dilute surfactant, has been investigated in both laboratory and clinical settings as a treatment for meconium aspiration syndrome (MAS). Studies in animal models of MAS have affirmed that dilute surfactant lavage can remove meconium from the lung, with resultant improvement in lung function. In human infants both non-randomised studies and two randomised controlled trials have demonstrated a potential benefit of dilute surfactant lavage over standard care. The largest clinical trial, performed by our research group in infants with severe MAS, found that lung lavage using two 15-ml/kg aliquots of dilute surfactant did not reduce the duration of respiratory support, but did appear to reduce the composite outcome of death or need for extracorporeal membrane oxygenation. A further trial of lavage therapy is planned to more precisely define the effect on survival. Innovative approaches to surfactant therapy have also extended to the preterm infant, for whom the more widespread use of continuous positive airway pressure (CPAP) has meant delaying or avoiding administration of surfactant. In an effort to circumvent this problem, less invasive techniques of bolus surfactant therapy have been trialled, including instillation directly into the pharynx, via laryngeal mask and via brief tracheal catheterisation. In a recent clinical trial, instillation of surfactant into the trachea using a flexible feeding tube was found to reduce the need for subsequent intubation. We have developed an alternative method of brief tracheal catheterisation in which surfactant is delivered via a semi-rigid vascular catheter inserted through the vocal cords under direct vision. In studies to date, this technique has been relatively easy to perform, and resulted in rapid improvement in lung function and reduced need for subsequent ventilation and duration of oxygen therapy. We are now commencing large-scale clinical trials of this method in preterm infants on CPAP.
机译:自药物上市以来,外源性表面活性剂治疗领域的创新持续了二十多年。在实验室和临床环境中都研究了一种这样的创新方法,即使用稀释的表面活性剂进行肺灌洗,以治疗胎粪吸入综合征(MAS)。在MAS动物模型中进行的研究证实,稀释的表面活性剂灌洗可以从肺中去除胎粪,从而改善肺功能。在人类婴儿中,非随机研究和两项随机对照试验均表明,与标准护理相比,稀释表面活性剂灌洗具有潜在的好处。由我们的研究小组在患有严重MAS的婴儿中进行的最大的临床试验发现,使用两个15 ml / kg等分稀释表面活性剂的肺灌洗液并不能减少呼吸支持的持续时间,但确实可以减少死亡的综合结果或需要体外膜氧合。计划进行进一步的灌洗疗法试验,以更精确地确定其对生存的影响。表面活性剂治疗的创新方法也已扩展到早产儿,对于他们来说,连续气道正压通气(CPAP)的更广泛使用意味着延迟或避免表面活性剂的给药。为了解决这个问题,已经尝试了侵入性表面活性剂治疗的微创技术,包括通过喉罩和短暂的气管导管直接滴入咽。在最近的一项临床试验中,发现使用挠性喂食管将表面活性剂滴入气管可减少后续插管的需要。我们已经开发了一种简短的气管导管插入方法,其中表面活性剂是通过在直视下通过声带插入的半刚性血管导管输送的。在迄今为止的研究中,该技术相对易于实施,并导致肺功能的快速改善,并减少了随后通气的需要和氧气治疗的持续时间。我们现在开始在CPAP早产儿中使用此方法进行大规模临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号